Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

  1. March 05, 2024

    Avadel Told To Pay Jazz Pharma $234K Over Narcolepsy Drug IP

    A Delaware federal jury found Monday that a specialty drugmaker owes nearly $234,000 to drug manufacturer Jazz Pharmaceuticals Inc. for using a patented process behind its newer narcolepsy drug, launched last year to sales of over $28 million.

  2. February 15, 2024

    IP Forecast: 'No Labels' Party Feuds With Website Over Name

    In advance of debuting candidates for its promised "Unity Ticket for 2024," third-party political group No Labels will fight next week with a website's owners who say the group's name is merely a generic phrase any candidate can use. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.

  3. December 14, 2022

    Fed. Circ. Pauses 'Orange Book' Delisting For Jazz Drug

    Jazz Pharmaceuticals will be allowed to list its patent for a narcolepsy drug in health regulators' roster of approved drugs, at least for the near future, after the Federal Circuit granted the company's request to extend a stay of the delistment order Wednesday.

  4. December 05, 2022

    Del. Court Won't Pause 'Orange Book' Delisting

    A Delaware federal court on Monday refused to pause an order requiring Jazz Pharmaceuticals to remove a patent for a narcolepsy drug from health regulators' listing of approved drugs, but the Federal Circuit is still considering a bid to stay the order.

  5. December 01, 2022

    Pharma Co. Slams Bid To Delay 'Orange Book' Delisting

    Avadel Pharmaceuticals criticized Jazz Pharmaceuticals' latest attempt to delay delisting of a patent that purportedly covers distribution of a narcolepsy drug from health regulators' so-called Orange Book, accusing Jazz of harming the public interest to protect the $5 million per day it makes from its oxybate products.

  6. November 23, 2022

    Pharma Co. Asks For Stay To Appeal 'Orange Book' Delisting

    Jazz Pharmaceuticals has asked a Delaware federal court to pause an order requiring it to ask the U.S. Food and Drug Administration to pull a patent that purportedly covers the distribution of a narcolepsy drug from the agency's so-called Orange Book while it appeals.

  7. November 18, 2022

    Del. Court Says Pharma Co. Must Delist 'Orange Book' Patent

    Jazz Pharmaceuticals has two weeks to ask the U.S. Food and Drug Administration to pull a patent that purportedly covers a narcolepsy drug from the agency's so-called Orange Book after a Delaware federal court found that it covers a distribution method and not the drug itself.

  8. November 14, 2022

    FTC Says "Orange Book" Abuse Blocks Drug Competition

    The Federal Trade Commission urged a Delaware federal court to remove a patent for narcolepsy drug distribution from federal regulators' list of approved drugs and the patents covering them, arguing the patent was improperly included and is blocking competition.